Conducting Quantitative Synthesis When Comparing Medical Interventions: AHRQ and the Effective Health Care Program
- PMID: 21433407
- Bookshelf ID: NBK49407
Conducting Quantitative Synthesis When Comparing Medical Interventions: AHRQ and the Effective Health Care Program
Excerpt
Objective: The objective is to establish recommendations for conducting quantitative synthesis or meta-analysis using study-level data in Comparative effectiveness reviews (CERs) for the Evidence-based Practice Center (EPC) program of the Agency for Healthcare Research and Quality (AHRQ).
Study Design and Setting: We focused on recurrent issues in the EPC program and the recommendations were developed using group discussion and consensus based on current knowledge in the literature.
Results: We first discussed considerations for deciding whether to combine studies, followed by discussions on indirect comparison and incorporation of indirect evidence. Then we described our recommendations on choosing effect measures and statistical models, giving special attention to combining studies with rare events, and on testing and exploring heterogeneity. Finally, we briefly present recommendations on combining studies of mixed design and on sensitivity analysis.
Conclusion: Quantitative synthesis should be conducted in a transparent and consistent way. Inclusion of multiple alternative interventions in CERs increases the complexity of quantitative synthesis while the basic issues in quantitative synthesis remain crucial considerations in quantitative synthesis for a CER. We will cover more issues in future versions and update and improve recommendations with the accumulation of new research to advance the goal for transparency and consistency.
Sections
References
-
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471. - PubMed
-
- Dahabreh IJ, Economopoulos K. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials. 2008;5:116–120. - PubMed
-
- Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147:578–581. - PubMed
-
- Shuster JJ, Jones LS, Salmon DA. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Stat Med. 2007;26:4375–4385. - PubMed
-
- Committee on Oversight and Government Reform. Hearing on FDA’s Role in Evaluating Safety of Avandia. [Accessed May 31, 2010]. Available at: http://oversight.house.gov/index.php?option=com_content&view=article&id=....
Publication types
LinkOut - more resources
Full Text Sources